Brian H Ladle
Overview
Explore the profile of Brian H Ladle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chidiac C, McDermott K, Ramdat C, Price M, Greer J, Ladle B, et al.
J Surg Oncol
. 2025 Jan;
PMID: 39780459
Background And Objectives: Neuroblastoma, the most common extracranial solid tumor in children, is rare in adults. This study compares patient characteristics, disease patterns, and treatments among adults, adolescents, and children...
2.
Murphy J, Sundby R, Resch E, Rahnama R, Lemberg K, Maalouf A, et al.
Curr Oncol
. 2024 Nov;
31(11):7014-7022.
PMID: 39590147
Background: Brain metastases in pediatric osteosarcoma are infrequent but associated with a dire prognosis. Methods: This retrospective study examined six pediatric patients at Johns Hopkins Hospital who developed brain metastases...
3.
Zhang L, Maalouf A, Makri S, Banerjee J, Suru A, Tam A, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5459-5472.
PMID: 39321200
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas and the leading cause of mortality in individuals with neurofibromatosis type 1 (NF1). Despite many clinical trials, outcomes for...
4.
Chang L, DAmiano A, Bhatia R, Yenokyan G, Llosa N, Ladle B, et al.
Int J Radiat Oncol Biol Phys
. 2023 Oct;
118(2):474-484.
PMID: 37797747
Purpose: To determine the association between consolidative radiation (RT) and survival in children, adolescents, and young adults with metastatic sarcoma. Methods And Materials: Eligibility criteria included patients aged ≤39 years...
5.
Chen A, Sharon E, OSullivan-Coyne G, Moore N, Foster J, Hu J, et al.
N Engl J Med
. 2023 Sep;
389(10):911-921.
PMID: 37672694
Background: Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported. Methods:...
6.
Parida S, Siddharth S, Gatla H, Wu S, Wang G, Gabrielson K, et al.
Front Immunol
. 2023 Jul;
14:1194931.
PMID: 37503343
Introduction: Obesity, an independent risk factor for breast cancer growth and metastatic progression, is also closely intertwined with gut dysbiosis; and both obese state and dysbiosis promote each other. Enteric...
7.
Zou Y, Morsberger L, Hardy M, Ghabrial J, Stinnett V, Murry J, et al.
Genes (Basel)
. 2023 Jun;
14(6).
PMID: 37372318
Ewing sarcomas (ES) are rare small round cell sarcomas often affecting children and characterized by gene fusions involving one member of the FET family of genes (usually and a member...
8.
Hensel J, Metts J, Gupta A, Ladle B, Pilon-Thomas S, Mullinax J
Cancer J
. 2022 Jul;
28(4):322-327.
PMID: 35880942
Children and adolescents with high-risk (metastatic and relapsed) solid tumors have poor outcomes despite intensive multimodal therapy, and there is a pressing need for novel therapeutic strategies. Adoptive cellular therapy...
9.
Liu T, Merguerian M, Rowe S, Pratilas C, Chen A, Ladle B
Cold Spring Harb Mol Case Stud
. 2021 Jul;
7(4).
PMID: 34210658
Treatment of high-risk neuroblastoma typically incorporates multiagent chemotherapy, surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and differentiation therapy. The discovery of activating mutations in ALK receptor tyrosine kinase ()...
10.
Ladle B
Cancer Res
. 2021 May;
81(8):1940-1941.
PMID: 34003772
Despite being one of the earliest immunotherapies to prove that the immune system can effectively recognize and eradicate cancer, autologous adoptive T-cell therapies remain largely limited to academic centers and...